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Thalidomide for the treatment of metastatic hepatic epithelioid
hemangioendothelioma: A case report with a long term follow-up
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ABSTRACT
Hepatic epithelioid hemangioendothelioma (HEH) is an unusual, low-grade malignant vascular tumor of the
liver. Here we describe a case of a 40-year-old woman who presented with abdominal pain in the upper
right quadrant and giant hepatomegaly, in which imaging studies and a fine-needle liver biopsy confirmed
the presence of a large EHE with an isolated lung metastasis. After balancing all possible therapeutic mo-
dalities the patient was treated conservatively with thalidomide (300 mg/day). The drug was well tolerated
with minimal toxicity and the patient continues on therapy 109 months after treatment was started with
no disease progression. Current therapeutic options for HEH are discussed in light of the clinical case with
particular emphasis on anti-angiogenic therapies.
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CASE REPORT
INTRODUCTION
Epithelioid hemangioendotheliomas are rare, low-
grade malignant neoplasms of endothelial origin
that belong to a group of soft tissue vascular tu-
mors with an intermediate clinical course between
benign hemangioma and angiosarcoma. This group
of tumors was first described by Weiss and Enzinger
in 19821 and has been observed in both soft tissues
and solid organs including liver, lungs, bones,
spleen and brain. Although the liver is among the
commonest viscera where the tumor has been found,
primary hepatic epithelioid hemangioendothelioma
(HEH) is considered an extremely rare neoplasm
with a reported incidence of less than 0.1 per
100,000 population and less than 200 cases reported
in the literature. The first series of 32 HEH patients
was reported in 1984 by Ishak. et al.2
Presentation, clinical course and prognosis
of HEH can vary widely.3 Although some patients
with HEH will present with exclusive hepatic disea-
se, the majority have multifocal disease at diagnosis
with extensive intrahepatic tumor burden and extra-
hepatic metastases.4 Given the low frequency of the
disease and its variable natural history, there are no
current guidelines for management and therapeutic
interventions are generally decided on a case by case
analysis. In patients with limited intrahepatic disea-
se, local resection is the treatment of choice, with li-
ver transplantation being an alternative in patients
with significant tumor burden.5-7 In metastatic di-
sease, treatment options include chemotherapy, ra-
diotherapy, hormone therapy, thermoablation,
percutaneous ethanol injection and follow-up with
no therapy.3,8
In this report, we describe a case of a patient
with HEH metastatic to the lungs who was trea-
ted with oral thalidomide therapy and presented no
evidence of disease progression after 109 months of
follow-up. In light of this case, we discuss current
therapeutic options for HEH with emphasis on
© 2019, Fundación Clínica Médica Sur, A.C. Published by Elsevier España S.L.U. This is an open access article under the CC BY-NC-ND 
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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using anti-angiogenic therapy which seems to have
been successful in arresting the progression of the
disease in the current case.
CASE REPORT
A 40-year-old Caucasian woman with HEH was
evaluated at the Liver Unit of the Pontificia Univer-
sidad Católica de Chile in June 2001. She presented
with abdominal pain in the upper right quadrant,
asthenia, anorexia and weight loss (15 Kg in six
months) and a Karnofsky index of 70 due to limited
physical activity that rendered her unable to work
with varying amount of assistance needed on daily
basis. She had received oral contraceptives for the
previous seven years and she had no history of alco-
hol abuse. The physical examination was remarka-
ble for giant hepatomegaly up to the right pelvis and
splenomegaly 8 cm below costal margin. Body weig-
ht was 44 kg, she was 1.65 m tall and her body mass
index (BMI) was 16.2 kg/m2. Laboratory studies
showed slightly increased (less than two-times upper
normal limit) alkaline phosphatase and γ-glutamyl-
transpeptidase. Other standard hematological and
biochemical tests were normal. An abdominal CT
scan showed diffuse liver enlargement with a single
mass that infiltrated extensively the right lobe of
the liver with extension into the left lobe. The pa-
tient had a secondary lesion in her left lung as well
as splenic metastases. An upper endoscopy was nor-
mal. A fine-needle liver biopsy was performed and
histopathological examination (Figure 1) showed
marked cellular atypia and positive staining for the
endothelial markers CD31 and CD34 confirming the
vascular nature of the tumor and contributing to
the diagnosis of HEH. The single lung nodule suspi-
cious for metastasis was excised using a videothora-
coscopic approach and histological examination
confirmed the diagnosis of epithelioid hemangioen-
dothelioma. After evaluation in the liver clinic, the
patient was considered unsuitable for liver trans-
plantation due to confirmed metastatic HEH and not
a candidate for loco-regional therapies due to the
large tumor burden. Thus and based on its anti-an-
giogenic effects, thalidomide-based therapy was offe-
red. The starting dose of thalidomide was 200 mg
per day, which was increased up to 300 mg per day
after a month. The treatment was well tolerated
without significant toxicity and with no evidence of
peripheral neuropathy. After 3 months of therapy,
she reported relief of abdominal pain and a subjecti-
ve reduction in hepatosplenomegaly. After six mon-
ths of receiving thalidomide, the patient was
Figure 1. A: Liver tissue involved with epithelioid hemangio-
endothelioma with significant cytologic atypia (hematoxylin and
eosin X 400). B and C: Positive immunohistochemical staining
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asymptomatic recovering her normal weight of 62
kg with a BMI of 22.8 kg/m2. Physical activity was
completely normal with a Karnofsky index of 100
and a successful return to work life. Serial abdomi-
nal CT scans performed during the follow-up (at 6,
12, 24, 36, 48 and 91 months). The last CT scan per-
formed after 91 months of treatment showed reduc-
tion of the tumor burden of up to 50% of the initial
volume (Figure 2). No evidence of recurrent pulmo-
nary metastases was found. After 109 months, the
patient remains clinically stable and continues re-
ceiving thalidomide at a dose of 300 mg per day with
no significant side effects.
DISCUSSION
Epithelioid hemangioendothelioma is an uncom-
mon vascular tumor of the liver with an unpredicta-
ble malignant potential and an intermediately
aggressive biological course in between benign he-
mangioma and the highly malignant angiosarco-
ma.3,8 Its etiology and risk factors are not clearly
known, but some possible etiologic factors include
exposition to oral contraceptives, vinyl chloride, as-
bestos and the radioactive compound thorium dioxi-
de, major trauma to the liver, viral hepatitis,
primary biliary cirrhosis and alcohol consumption.3
Clinical presentation may vary from asymptomatic
to the manifestations of portal hypertension or he-
patic failure.1,2 At the time of diagnosis, up to 25%
of patients are asymptomatic, incidentally diagnosed
by radiology images, such as ultrasound, CT scan
or MRI of the abdomen.9 Common clinical manifesta-
tions are right upper quadrant pain, hepatomegaly
and weight loss. Physical examination may be nor-
mal or reveal hepatomegaly, splenomegaly, jaundice
or signs of portal hypertension. In a recent review
of 434 HEH cases reported in literature the most
common clinical manifestations were right upper
quadrant pain (48.6%), hepatomegaly (20.4%), and
weight loss (15.6%).3 Most of these signs and
symptoms previously described were present in our
patient at the time of the diagnosis, but jaundice
and portal hypertension were absent.
Laboratory parameters are abnormal in 84% of
the patients, with altered liver chemistry tests being
most the most common finding.3 Tumor markers (al-
pha-fetoprotein, carcinoembryonic antigen, and CA
19-9) are characteristically normal and are suitable
for ruling out other primary or metastatic liver tu-
mors.
Imaging studies in HEH patients may show soli-
tary or diffuse nodular lesions with variable featu-
res on different techniques that suggest the
diagnosis.9,10 The use of dual-time-point hepatic
FDG-PET/CT imaging has also been recently shown
to be useful for HEH diagnosis.11 However, definiti-
ve diagnosis of HEH requires histopathologic exa-
mination.13 In general, open wedge or core biopsy is
sufficient to encompass the architectural features of
HEH. Then, diagnosis is confirmed, as it was in our
patient, by immunohistochemical demonstration of
endothelial differentiation (Figure 1). In fact, immu-
nohistochemistry staining is positive for endothelial
cell surface markers such as CD31, CD34 and factor
VIII-related antigen in nearly all cases of HEH (4).
Other markers such as the angiogenic vascular en-
dothelial growth factor (VEGF) and its receptors
have been found in HEH.12
The natural history of the disease is not well
understood. Analysis of untreated patients from
large series reveals a 5-year survival of only 5%.3
This poor prognosis contrast with isolated reports
of no progression or even spontaneous regression
of the tumor,13 emphasizing the unpredictable ma-
lignant potential of HEH. No standard therapeu-
tic strategies are at present established for HEH.
Management of the disease depends of the presen-
ce of dissemination at the time of the diagnosis.
Figure 2. Contrast-enhanced CT scan of the abdomen after
91 months of treatment with thalidomide in a patient with he-
patic epithelioid hemangioendothelioma. The tumor burden
diminished after therapy compared with baseline CT.
Characteristic’s findings show diffuse hepatosplenomegaly
with multiple focal hipervascular, with a target pattern of
enhancement in larger lesions in the liver and hipovascular
lesions in the spleen.
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Clinical series report that at the time of diagnosis
roughly 27% of the patients already have dissemi-
nated disease.4 Tumors restricted to the liver are
candidates to surgery, either local resection or li-
ver transplant.3,7 At the time of the diagnosis only
9% of patients presents with tumors susceptible to
be handled with local resection, consequently liver
transplantation has become the treatment of
choice in patients with HEH, with clinical series
showing encouraging results using this option
with survival rates of 73% at 10 years.7 HEH is
classically considered chemo and radiotherapy re-
sistant and, therefore, these approaches are not
considered useful in HEH.12  In our patient, the
presence of extrahepatic disease led us to exclude
transplantation as a treatment option and the use
of thalidomide as anti-angiogenic therapy was in-
tuitively proposed.14 At that time, no literature on
the topic was available. More recently, at least
two reports on the use of thalidomide in patients
with EHE have been published. Mascarenhas re-
ported the case of a man of 52 years-old with he-
mangioendotelioma of the liver with pulmonary
metastases, successfully treated with the use of
thalidomide15 and Kassam and Mandell16 incorpo-
rated thalidomide to a chemotherapeutic scheme
aiming to achieve an anti-angiogenic effect. In our
case we observed a reduction in liver size and a
significant improvement of the performance status
of the patient and no deterioration after more
than nine years of follow-up.
Experimental data suggest that the anti-angio-
genic potential of thalidomide is related to the in-
hibition of VEGF pathway.14 The fact that VEGF
and its receptor has been shown to be present in
HEH provide a rationale for the use of thalidomi-
de in HEH.12 In fact, to target the VEGF pa-
thway with newly-developed agents such as
bevacizumab as well as sunitinib, sorafenib, and
pazopanib represent promising therapeutic appro-
aches for HEH.17,18 Obviously, more studies are
needed to confirm the utility of these agents as
well as to identify which patients will benefit
from them. Nevertheless, given the rarity of
HEH and long term follow up needed to observe
the progression of the disease or appearance of
new lesions, it seems unlikely that controlled
studies will be available soon. Based on our limi-
ted experience, we suggest that, considering its
cost and safety profile, thalidomide is a reasona-
ble option of treatment in patients with metasta-
tic HEH compared with other anti-angiogenic
drugs such as bevacizumab.
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